MedTrace Logo

Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)

NCT00998751 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-12-11

No results posted yet for this study

Summary

The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.

Conditions

  • Gastro-intestinal Stromal Tumours

Interventions

DRUG

oral masitinib

7.5 mg/kg/day

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00998751 on ClinicalTrials.gov